CAMBRIDGE, Mass., Sept. 11, 2013 /PRNewswire/ -- Caldera Pharmaceuticals, and its subsidiary XRpro Corp, a provider of proprietary drug discovery services for high-throughput ion-channel inhibitor assays and enzyme activity assays, today announced the closing of a financing in the amount of $3,170,000 which was led by Taglich Brothers.
Gary Altman, President and CEO of Caldera Pharmaceuticals, Inc., and its subsidiary, XRpro Corp, stated, "This capital will support the expansion of our scientific staff, the purchase of scientific instruments for the development and validation of additional assays and the launch of our marketing campaign." He continued, "On behalf of the company, I thank the entire team at Taglich Brothers for their efforts and guidance."
About Caldera Pharmaceuticals (XRpro®)
XRpro® offers screening services, and assay development services, to drug discovery teams. The company offers several screens not found elsewhere including the ability to determine real-time kinetics of ion channel activity in populations of intact cells in vitro, and the high-throughput screening of approximately 10,000 compounds per day with no modifications to either the drug candidate or the target. The primary technology is based on label-free, high-throughput screening system that uses Molecular X-Ray Fluorescence™.
About Taglich Brothers
Founded in 1991, Taglich Brothers, Inc. is a full service brokerage firm specializing in the microcap segment of the market for publicly traded securities. We define the microcap market as companies with less than $250 million of stock outstanding. The firm has selected this unique niche for two reasons. First and foremost, the small cap market has historically outperformed the large cap market over the past 75 years. Second, this area of the market is virtually ignored by the larger ins
|SOURCE Caldera Pharmaceuticals|
Copyright©2012 PR Newswire.
All rights reserved